Dr Reddy’s launches generic chemotherapy drug in the US

Pharma manufacturer Dr. Reddy’s Laboratories said it launched a generic version of chemotherapy drug drug Alkeran.

The drug is used for palliative — or relief-oriented — treatment of multiple myeloma and epithelial carcinoma of the ovary.

The Alkeran brand and generic had U.S. sales of approximately $107 million MAT for the most recent twelve months ending in October 2017, Dr Reddy’s said.

The product, Melphalan Hydrochloride Injection, is a therapeutic equivalent generic version of Alkeran (melphalan hydrochloride) for injection in the United States.

It will be sold in a carton containing one singledose clear glass vial of freeze-dried melphalan hydrochloride equivalent to 50 mg melphalan and one 10 mL clear glass vial of sterile diluent, it said.